# Vidofludimus PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vidofludimus

> Vidofludimus, sponsored by IMMUNIC, INC. (IMUX): 7 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | vidofludimus |
| Codes |  |
| Sponsor | IMMUNIC, INC. (IMUX) https://sec-api.dev/companies/imux/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### October 9, 2023: interim data readout

- Status: completed, positive. Date confidence: exact. Stage: 3.
- First seen 2025-03-31, last confirmed 2026-02-26.
- SEC Form 10-Q (accession 0001280776-25-000008): "Our Phase 2 CALLIPER trial of vidofludimus calcium in PMS was designed to corroborate vidofludimus calcium's neuroprotective potential and to evaluate the clinical efficacy, safety and tolerability of vidofludimus calcium in a broad set of PMS patients to determine the suitability of advancing to a confirmatory Phase 3 program, On October 9, 2023, we announced positive interim data from the CALLIPER trial, showing biomarker evidence that vidofludimus calcium's activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective potential." https://www.sec.gov/Archives/edgar/data/1280776/000128077625000008/vtl-20250331.htm
- SEC Form 10-K (accession 0001280776-25-000005): "On October 9, 2023, we announced positive interim data from our Phase 2 CALLIPER trial of vidofludimus calcium in patients with PMS." https://www.sec.gov/Archives/edgar/data/1280776/000128077625000005/imux-20241231.htm
- SEC Form 10-K (accession 0001280776-26-000005): "On October 9, 2023, we announced positive interim data from the CALLIPER trial, showing biomarker evidence that vidofludimus calcium's activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective potential." https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/imux-20251231.htm
- SEC Form 10-Q (accession 0001280776-25-000012): "On October 9, 2023, we announced positive interim data from the CALLIPER trial, showing biomarker evidence that vidofludimus calcium's activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective potential." https://www.sec.gov/Archives/edgar/data/1280776/000128077625000012/vtl-20250630.htm
- SEC Form 10-K (accession 0001280776-25-000005): "On October 9, 2023, we announced positive interim data from the CALLIPER trial, showing biomarker evidence that vidofludimus calcium's activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective potential." https://www.sec.gov/Archives/edgar/data/1280776/000128077625000005/imux-20241231.htm
- SEC prospectus (424B) (accession 0001193805-25-000455): "On October 9, 2023, we announced positive interim data from the CALLIPER trial, showing biomarker evidence that vidofludimus calcium's activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective potential." https://www.sec.gov/Archives/edgar/data/1280776/000119380525000455/e664312_424b5-immunic.htm
- SEC Form 10-Q (accession 0001280776-25-000017): "On October 9, 2023, we announced positive interim data from the CALLIPER trial, showing biomarker evidence that vidofludimus calcium's activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective potential." https://www.sec.gov/Archives/edgar/data/1280776/000128077625000017/vtl-20250930.htm
- SEC prospectus (424B) (accession 0001193805-25-000756): "On October 9, 2023, we announced positive interim data from the CALLIPER trial, showing biomarker evidence that vidofludimus calcium's activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective potential." https://www.sec.gov/Archives/edgar/data/1280776/000119380525000756/e664565_424b5-immunic.htm
- SEC prospectus (424B) (accession 0001193805-25-000731): "On October 9, 2023, we announced positive interim data from the CALLIPER trial, showing biomarker evidence that vidofludimus calcium's activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective potential." https://www.sec.gov/Archives/edgar/data/1280776/000119380525000731/e664548_424b5-immunic.htm

### October 22, 2024: interim data readout

- Status: completed, positive. Date confidence: exact. Stage: 3.
- First seen 2025-03-31, last confirmed 2026-08-11.
- SEC Form 10-Q (accession 0001280776-25-000012): "On October 22, 2024, we announced a positive outcome of an interim analysis of the ENSURE program, with an unblinded Independent Data Monitoring Committee ("IDMC") confirming that the predetermined futility criteria have not been met and recommending that both ENSURE trials should continue without changes, including no need for a potential increase of the sample size." https://www.sec.gov/Archives/edgar/data/1280776/000128077625000012/vtl-20250630.htm
- SEC Form 10-Q (accession 0001280776-25-000008): "On October 22, 2024, we announced a positive outcome of an interim analysis of the ENSURE program, with an unblinded Independent Data Monitoring Committee ("IDMC") confirming that the predetermined futility criteria have not been met and recommending that both ENSURE trials should continue without changes, including no need for a potential increase of the sample size." https://www.sec.gov/Archives/edgar/data/1280776/000128077625000008/vtl-20250331.htm
- SEC Form 10-K (accession 0001280776-25-000005): "Moreover, on October 22, 2024, we announced a positive outcome of an interim analysis of the ENSURE program, with an unblinded Independent Data Monitoring Committee ("IDMC") confirming that the predetermined futility criteria have not been met and recommending that both ENSURE trials should continue without changes, including no need for a potential increase of the sample size." https://www.sec.gov/Archives/edgar/data/1280776/000128077625000005/imux-20241231.htm
- SEC Form 10-Q (accession 0001280776-26-000018): "In October 2024, we announced a positive outcome of an interim analysis of the ENSURE program, with an unblinded Independent Data Monitoring Committee ("IDMC") confirming that the predetermined futility criteria have not been met and recommending that both ENSURE trials should continue without changes, including no need for a potential increase of the sample size." https://www.sec.gov/Archives/edgar/data/1280776/000128077626000018/vtl-20260630.htm
- SEC Form 10-K (accession 0001280776-26-000005): "In October 2024, we announced a positive outcome of an interim analysis of the ENSURE program, with an unblinded Independent Data Monitoring Committee ("IDMC") confirming that the predetermined futility criteria have not been met and recommending that both ENSURE trials should continue without changes, including no need for a potential increase of the sample size." https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/imux-20251231.htm
- SEC Form 10-K (accession 0001280776-25-000005): "On October 22, 2024, we announced a positive outcome of an interim analysis of our Phase 3 ENSURE program, investigating vidofludimus calcium for the treatment of RMS." https://www.sec.gov/Archives/edgar/data/1280776/000128077625000005/imux-20241231.htm
- SEC prospectus (424B) (accession 0001193805-25-000455): "On October 22, 2024, we announced a positive outcome of an interim analysis of our Phase 3 ENSURE program, investigating vidofludimus calcium for the treatment of RMS." https://www.sec.gov/Archives/edgar/data/1280776/000119380525000455/e664312_424b5-immunic.htm

### Apr 2025: topline data readout

- Status: scheduled. Date confidence: month. Stage: 2.
- First seen 2025-03-31, last confirmed 2025-03-31.
- SEC Form 10-K (accession 0001280776-25-000005): "◦release by the Company of topline data from its Phase 2b clinical trial of vidofludimus calcium (IMU-838) in progressive multiple sclerosis, which data is currently expected in or around April 2025;" https://www.sec.gov/Archives/edgar/data/1280776/000128077625000005/imux-20241231.htm
- SEC Form 10-K (accession 0001280776-25-000005): "•release by the Company of topline data from its Phase 2b clinical trial of vidofludimus calcium (IMU-838) in progressive multiple sclerosis, which data is currently expected in or around April 2025;" https://www.sec.gov/Archives/edgar/data/1280776/000128077625000005/imux-20241231.htm

### June 5, 2025: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-03-31, last confirmed 2026-02-26.
- SEC Form 10-Q (accession 0001280776-25-000012): "On June 5, 2025, we announced additional data from our Phase 2 CALLIPER trial in PMS, further supporting the positive top-line results announced on April 30, 2025, and underlining vidofludimus calcium's neuroprotective potential." https://www.sec.gov/Archives/edgar/data/1280776/000128077625000012/vtl-20250630.htm
- SEC Form 10-K (accession 0001280776-26-000005): "On June 5, 2025, we also announced additional data from our Phase 2 CALLIPER trial in PMS, further supporting the positive top-line results announced on April 30, 2025." https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/imux-20251231.htm
- SEC Form 10-K (accession 0001280776-25-000005): "Top-line data from the CALLIPER trial, for which the recruitment of 467 total patients was completed in August 2023, is expected to be available in April 2025." https://www.sec.gov/Archives/edgar/data/1280776/000128077625000005/imux-20241231.htm
- SEC Form 10-K (accession 0001280776-25-000005): "Our current expectation is to read-out top-line data of the CALLIPER trial in April 2025." https://www.sec.gov/Archives/edgar/data/1280776/000128077625000005/imux-20241231.htm
- SEC Form 10-Q (accession 0001280776-25-000017): "On June 5, 2025, we announced additional data from our Phase 2 CALLIPER trial in PMS, further supporting the positive top-line results announced on April 30, 2025." https://www.sec.gov/Archives/edgar/data/1280776/000128077625000017/vtl-20250930.htm

### late 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-11-13, last confirmed 2025-11-13.
- Press release filed with the SEC (EX-99) (accession 0001193805-25-001570): "Top-Line Data from Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End" https://www.sec.gov/Archives/edgar/data/1280776/000119380525001570/e664954_ex99-1.htm

### late 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-08-11, last confirmed 2026-08-11.
- SEC Form 10-Q (accession 0001280776-26-000018): "Initiation of a Phase 3 clinical trial of vidofludimus calcium in progressive MS is expected later in 2026." https://www.sec.gov/Archives/edgar/data/1280776/000128077626000018/vtl-20260630.htm

### late 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-03-31, last confirmed 2026-08-11.
- SEC Form 10-K (accession 0001280776-26-000005): "Our most advanced product candidate, vidofludimus calcium, had the first patient enrolled in a Phase 3 program for relapsing multiple sclerosis ("RMS") in November 2021 and we do not expect the readout of topline data from this trial until the end of 2026." https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/imux-20251231.htm
- SEC Form 10-K (accession 0001280776-25-000005): "Our most advanced product candidate, vidofludimus calcium, had the first patient enrolled in a Phase 3 program for relapsing multiple sclerosis ("RMS") in November 2021 and we do not expect the readout of topline data from this trial until the middle of 2026." https://www.sec.gov/Archives/edgar/data/1280776/000128077625000005/imux-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001193805-25-001164): "Vidofludimus calcium in MS: Top-line data from the twin phase 3 ENSURE-1 and ENSURE-2 trials is expected by the end of 2026." https://www.sec.gov/Archives/edgar/data/1280776/000119380525001164/e664768_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001193805-26-001071): ""Our Phase 3 ENSURE trials of vidofludimus calcium in relapsing MS remain on track to report top-line data by the end of 2026," added Michael A. Panzara, M.D., M.P.H., Chief" https://www.sec.gov/Archives/edgar/data/1280776/000119380526001071/e665684_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001193805-26-001071): "Vidofludimus Calcium in Relapsing MS: Top-line data from the twin Phase 3 ENSURE-1 and ENSURE-2 trials remains on track and is expected to be available by the end of 2026." https://www.sec.gov/Archives/edgar/data/1280776/000119380526001071/e665684_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001193805-26-000593): "Continued to Execute Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis, with Top-Line Data Expected by End of 2026 -" https://www.sec.gov/Archives/edgar/data/1280776/000119380526000593/e665461_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001193805-26-000129): "Completion of the ongoing phase 3 ENSURE clinical trials of vidofludimus calcium in relapsing multiple sclerosis (RMS): Top-line data continues to be expected by the end of 2026." https://www.sec.gov/Archives/edgar/data/1280776/000119380526000129/e665154_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001193805-26-001071): "Erik Lundgren, Chief Executive Officer of Immunic, added, "With top-line data from our Phase 3 ENSURE trials of vidofludimus calcium in relapsing multiple sclerosis (MS) expected by year-end and the planned initiation of our confirmatory Phase 3 program in progressive MS, we are executing towards a series of milestones that have the potential to define Immunic's next phase of growth." https://www.sec.gov/Archives/edgar/data/1280776/000119380526001071/e665684_ex99-1.htm
- SEC Form 10-Q (accession 0001280776-26-000018): "The top-line data for both ENSURE trials is expected by the end of 2026." https://www.sec.gov/Archives/edgar/data/1280776/000128077626000018/vtl-20260630.htm
- SEC Form 10-K (accession 0001280776-26-000005): "The top-line data for both ENSURE trials is expected by the end of 2026." https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/imux-20251231.htm
- SEC Form 10-K (accession 0001280776-26-000005): "The top-line data from both ENSURE trials is expected by the end of 2026, which should allow for a synchronized readout and a pooled assessment of the confirmed disability worsening secondary endpoint." https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/imux-20251231.htm
- SEC Form 10-Q (accession 0001280776-25-000012): "The top-line data for both ENSURE trials is expected by the end of 2026." https://www.sec.gov/Archives/edgar/data/1280776/000128077625000012/vtl-20250630.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vidofludimus.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Vidofludimus PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vidofludimus

```bibtex
@misc{secapidev_pdufa_vidofludimus_20261116,
  title        = {Vidofludimus PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vidofludimus}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vidofludimus_20261116","title":"Vidofludimus PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vidofludimus","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
